Overview

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
Phase:
Phase 4
Details
Lead Sponsor:
Galderma
Galderma R&D
Treatments:
Adapalene